重视慢性心力衰竭恶化的患者管理

孔洪

doi:10.13201/j.issn.1001-1439.2021.04.001

重视慢性心力衰竭恶化的患者管理

孔洪^,

- 四川省医学科学院·四川省人民医院心血管内科(成都,610072)

详细信息

通讯作者: 孔洪,E-mail:18981838250@163.com

中图分类号: R542.2

收稿日期: 2021-03-10

The management of patients with worsening chronic heart failure should be emphasized

KONG Hong^,

- Depatment of Cardiology,Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, 610072, China

More Information

Corresponding author: KONG Hong, E-mail: 18981838250@163.com

Received Date: 10 March 2021

摘要

摘要: 慢性心力衰竭(心衰)恶化是心衰症状和临床状态未得到改善甚至恶化,进入终末期心衰的表现,是心衰病程中的一个阶段,目前国内外尚未有统一的定义。针对该阶段临床上需要重视和加强院内外长期一体化管理。早期识别,优化方案,并将改善心衰预后的新型药物早期规模化应用。
- 心力衰竭 /
- 慢性心力衰竭恶化 /
- 射血分数 /
- 心力衰竭管理
Abstract: Deterioration of chronic heart failure manifests that the symptoms and clinical status of heart failure are not improved or even worsen into end-stage heart failure. It is a stage in the course of heart failure. There is no unified definition for this stage so far.Given this stage, we need to pay attention to strengthening the long-term integrated management inside and outside the hospital. Early identification, optimization of the program, and large-scale application of new drugs to improve the prognosis of heart failure are desirable.
- heart failure /
- deterioration of chronic heart failure /
- ejection fraction /
- management of heart failure

HTML全文

参考文献(31)

[1]	Richardson H.Frusemide in heart failure of infancy[J].Arch Dis Child,1971,46(248):520-524.
[2]	Metra M,Ravera A,Filippatos G,et al.Understanding worsening heart failure as a therapeutic target:another step forward?[J].Eur J Heart Fail,2017,19(8):996-1000.
[3]	Greene SJ,Mentz RJ,Felker GM.Outpatient Worsening Heart Failure as a Target for Therapy:A Review[J].JAMA Cardiol,2018,3(3):252-259.
[4]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[5]	EMA.CPMP/EWP/235/95,Rev.2.Published July 20,2017.Accessed July 23,2019.
[6]	Santos-Gallego CG,Vargas-Delgado AP,Requena-Ibanez JA,et al.Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction[J].J Am Coll Cardiol,2021,77(3):243-255.
[7]	Cowie MR,Anker SD,Cleland J,et al.Improving care for patients with acute heart failure:before,during and after hospitalization[J].ESC Heart Fail,2014,1(2):110-145.
[8]	Okumura N,Jhund PS,Gong J,et al.Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting:Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial(PARADIGM-HF)[J].Circulation,2016,133(23):2254-2262.
[9]	Okumura N,Jhund PS,Gong J,et al.Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting:Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial(PARADIGM-HF)[J].Circulation,2016,133(23):2254-2262.
[10]	Butler J,Yang M,Manzi MA,et al.Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction[J].J Am Coll Cardiol,2019,73(8):935-944.
[11]	Hollenberg SM,Warner Stevenson L,Ahmad T,et al.2019 ACC Expert Consensus Decision Pathway on Risk Assessment,Management,and Clinical Trajectory of Patients Hospitalized With Heart Failure:A Report of the American College of Cardiology Solution Set Oversight Committee[J].J Am Coll Cardiol,2019,74(15):1966-2011.
[12]	Mentz RJ,O'Connor CM.Pathophysiology and clinical evaluation of acute heart failure[J].Nat Rev Cardiol,2016,13(1):28-35.
[13]	张健,张宇辉.多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析[J].中国循环杂志,2015,30(5):413-416.
[14]	Nieminen MS,Brutsaert D,Dickstein K,et al.EuroHeart Failure Survey Ⅱ(EHFS Ⅱ):a survey on hospitalized acute heart failure patients:description of population[J].Eur Heart J,2006,27(22):2725-2736.
[15]	Greene SJ,Butler J,Albert NM,et al.Medical Therapy for Heart Failure With Reduced Ejection Fraction:The CHAMP-HF Registry[J].J Am Coll Cardiol,2018,72(4):351-366.
[16]	Huang J,Yin H,Zhang M,et al.Understanding the economic burden of heart failure in China:impact on disease management and resource utilization[J].J Med Econ,2017,20(5):549-553.
[17]	Ruppar TM,Cooper PS,Mehr DR,et al.Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates:Systematic Review and Meta-Analysis of Controlled Trials[J].J Am Heart Assoc,2016,5(6).
[18]	范惠华,史浩颖,金炜,等.三级医院心力衰竭门诊管理方案对患者预后的影响[J].中华心血管病杂志,2010,38(7):592-596.
[19]	Ouwerkerk W,Voors AA,Anker SD,et al.Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure:a prospective European study[J].Eur Heart J,2017,38(24):1883-1890.
[20]	Kido K,Bianco C,Caccamo M,et al.Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction[J].Ann Pharmacother,2020:1060028020983522.
[21]	Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,18(8):891-975.
[22]	Papp Z,Agostoni P,Alvarez J,et al.Levosimendan Efficacy and Safety:20 Years of SIMDAX in Clinical Use[J].J Cardiovasc Pharmacol,2020,76(1):4-22.
[23]	Lilleberg J,Laine M,Palkama T,et al.Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure[J].Eur J Heart Fail,2007,9(1):75-82.
[24]	Crespo-Leiro MG,Metra M,Lund LH,et al.Advanced heart failure:a position statement of the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail,2018,20(11):1505-1535.
[25]	Lewis EF,Claggett BL,McMurray J,et al.Health-Related Quality of Life Outcomes in PARADIGM-HF[J].Circ Heart Fail,2017,10(8).
[26]	Zannad F,Ferreira JP,Pocock SJ,et al.SGLT2 inhibitors in patients with heart failure with reduced ejection fraction:a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J].Lancet,2020,396(10254):819-829.
[27]	Packer M,Anker SD,Butler J,et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J].N Engl J Med,2020,383(15):1413-1424.
[28]	Petrie MC,Verma S,Docherty KF,et al.Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes[J].JAMA,2020,323(14):1353-1368.
[29]	Docherty KF,Jhund PS,Inzucchi SE,et al.Effects of dapagliflozin in DAPA-HF according to background heart failure therapy[J].Eur Heart J,2020,41(25):2379-2392.
[30]	Martinez FA,Serenelli M,Nicolau JC,et al.Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age:Insights From DAPA-HF[J].Circulation,2020,141(2):100-111.
[31]	Armstrong PW,Pieske B,Anstrom KJ,et al.Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction[J].N Engl J Med,2020,382(20):1883-1893.